# Treatment response in chronic urticaria: analysis of clinical and laboratory predictors

## TL;DR

This study identifies clinical factors like high BMI and mental disorders that predict poor treatment response in chronic urticaria patients.

## Contribution

The study provides new insights into clinical predictors of treatment response in chronic urticaria.

## Key findings

- Higher BMI, female gender, and mental disorders correlate with poor treatment outcomes.
- Early onset and longer disease duration are linked to reduced response to antihistamines.
- Laboratory tests like IgE and CRP do not predict treatment response.

## Abstract

Chronic urticaria (CU) compromises quality of life, requiring escalated treatment with second-generation H1 antihistamines, omalizumab, and, in refractory cases, cyclosporine. Predictors of therapeutic response are not yet well established.

To evaluate clinical and laboratory factors associated with treatment response in patients with CU.

Cross-sectional study of 175 patients with CU followed at the Urticaria Reference Center (UCARE) of Complexo Hospitalar Universitário Professor Edgard Santos (HUPES/UFBA) between 2023 and 2024. Sociodemographic, clinical, and laboratory data were analyzed. Treatment response was assessed using the Urticaria Control Test (UCT), with responders being those with a score ≥12 or Angioedema Control Test (AECT) ≥10.

Most patients were female (80.6%), with a mean age of 45.3 years. Chronic spontaneous urticaria (CSU) was predominant (86.3%). Higher body mass index (BMI), early onset, longer disease duration, and psychiatric disorders were associated with poorer response to second-generation H1 antihistamines. Responders to these drugs had shorter disease duration and a lower proportion of women compared to those requiring omalizumab. In omalizumab users, mental disorders remained associated with refractoriness. Total IgE, eosinophils, CRP, ESR, D-dimer, and anti-TPO did not correlate with therapeutic response.

Cross-sectional study and reliance on clinical records, information bias, and selection bias.

High BMI, female gender, early symptom onset, prolonged disease duration, and mental disorders were associated with poorer response to CU treatment. The evaluated laboratory tests did not demonstrate predictive value for treatment response.